KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis

Antiviral Research

Volumn 67, Issue 1, 2005, Pages 1-9

  Harris, Kevin S ^a   Brabant, William ^a   Styrchak, Sheila ^a   Gall, Alexander ^a   Daifuku, Richard ^a  

^a Koronis Pharmaceuticals   (United States)

Author keywords

HIV; Mutagenesis; Novel nucleoside analog

Indexed keywords

5 AZA 5,6 DIHYDRO 2' DEOXYCYTIDINE; ABACAVIR; KP 1212; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DNA SYNTHESIS; DRUG EFFECT; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; AZACITIDINE; CELL LINE; CRICETINAE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 20444414897     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.03.004     Document Type: Article

References (32)

1. K.M. Ayers, D. Clive, W.E. Tucker Jr., G. Hajian, and P. de Miranda Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats Fundam. Appl. Toxicol. 32 1996 148 158
2. J. Balzarini, M.J. Camarasa, M.J. Pérez-Pérez, A. San-Félix, S. Velazquez, C.F. Perno, E. De Clercq, J.N. Anderson, and A. Karlsson Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV J. Virol. 75 2001 5772 5777
3. G. Birkus, M.J.M. Hitchcock, and T. Cihlar Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors Antimicrob. Agents Chemother. 46 2002 716 723
4. J.M. Coffin HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 1995 483 489
5. J.M. Covey, M. D'Incalci, E.J. Tilchen, D.S. Zaharko, and K.W. Kohn Differences in DNA damage produced by incorporation of 5-aza-2′- deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells Cancer Res. 46 1986 5511 5517
6. E.T. Creagan, D.J. Schaid, L.C. Hartmann, and C.L. Loprinzi A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma Am. J. Clin. Oncol. 16 1993 243 244
7. S. Crotty, D. Maag, J.J. Arnold, W. Zhong, J.Y. Lau, Z. Hong, R. Andino, and C.E. Cameron The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Nat. Med. 6 2000 1375 1379
8. S. Crotty, C.E. Cameron, and R. Andino RNA virus error catastrophe: direct molecular test by using ribavirin Proc. Natl. Acad. Sci. U.S.A. 98 2001 6895 6900
9. G.A. Curt, J.A. Kelley, R.L. Fine, P.N. Huguenin, J.S. Roth, G. Batist, J. Jenkins, and J.M. Collins A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880) Cancer Res. 45 1985 3359 3363
10. R. Daifuku Stealth nucleosides: mode of action and potential use in the treatment of viral diseases BioDrugs 17 2003 169 177
11. M. Eigen Viral quasispecies Sci. Am. 269 1993 42 49
12. J.Y. Feng, A.A. Johnson, K.A. Johnson, and K.S. Anderson Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs J. Biol. Chem. 276 2001 23832 23837
13. P.J. Gerrish, and J.G. Garcia-Lerma Mutation rate and the efficacy of antimicrobial drug treatment Lancet Infect. Dis. 3 2003 28 32
14. A.A. Johnson, A.S. Ray, J. Hanes, Z. Suo, J.M. Colacino, K.S. Anderson, and K.A. Johnson Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase J. Biol. Chem. 276 2001 40847 40857
15. R. Kantor, R. Machekano, M.J. Gonzales, K. Dupnik, J.M. Schapiro, and R.W. Shafer Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs Nucleic Acids Res. 29 2001 296 299
16. U.R. Kees, and V.I. Avramis Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163 Anticancer Drugs 6 1995 303 310
17. B.A. Larder, B. Chesebro, and D.D. Richman Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay Antimicrob. Agents Chemother. 34 1990 436 441
18. B.A. Larder, K.E. Coates, and S.D. Kemp Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture J. Virol. 65 1991 5232 5236
19. L.A. Loeb, J.M. Essigmann, F. Kazazi, J. Zhang, K.D. Rose, and J.I. Mullins Lethal mutagenesis of HIV with mutagenic nucleoside analogs Proc. Natl. Acad. Sci. U.S.A. 96 1999 1492 1497
20. B.S. Mandavilli, J.H. Santos, and B. Van Houten Mitochondrial DNA repair and aging Mutat. Res. 509 2002 127 151
21. Murakami, E., Basavapathruni, A., Bradley, W., Anderson, K.S., 2005. Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res.
22. M. Nowak, and P. Schuster Error thresholds of replication in finite populations mutation frequencies and the onset of Muller's ratchet J. Theor. Biol. 137 1989 375 395
23. U. O'Doherty, W.J. Swiggard, and M.H. Malim Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding J. Virol. 74 2000 10074 10080
24. J.P. O'Neill, P.A. Brimer, R. Machanoff, G.P. Hirsch, and A.W. Hsie A quantitative assay of mutation induction at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells (CHO/HGPRT system): development and definition of the system Mutat. Res. 45 1977 91 101
25. J.P. O'Neill, and A.W. Hsie Chemical mutagenesis of mammalian cells can be quantified Nature 269 1977 815 817
26. N. Pariente, S. Sierra, P.R. Lowenstein, and E. Domingo Efficient virus extinction by combinations of a mutagen and antiviral inhibitors J. Virol. 75 2001 9723 9730
27. B.D. Preston, B.J. Poiesz, and L.A. Loeb Fidelity of HIV-1 reverse transcriptase Science 242 1988 1168 1171
28. J.D. Roberts, K. Bebenek, and T.A. Kunkel The accuracy of reverse transcriptase from HIV-1 Science 242 1988 1171 1173
29. B.L. Samuels, J.E. Herndon II, D.C. Harmon, R. Carey, J. Aisner, J.M. Corson, Y. Suzuki, M.R. Green, and N.J. Vogelzang Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the cancer and leukemia group B Cancer 82 1998 1578 1584
30. H.E. Sussman, O.A. Olivero, Q. Meng, S.M. Pietras, M.C. Poirie, J.P. O'Neill, B.A. Finette, M.J. Bauer, and V.E. Walker Genotoxicity of 3′-azido-3′-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT Mutat. Res. 429 1999 249 259
31. D. Wang, D.A. Kreutzer, and J.M. Essigmann Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions Mutat. Res. 400 1998 99 115
32. R.D. Wood, M. Mitchell, J. Sgouros, and T. Lindahl Human DNA repair genes Science 291 2001 1284 1289